Multifunctional nanoparticles precisely reprogram the tumor microenvironment and potentiate antitumor immunotherapy after near-infrared-II light-mediated photothermal therapy
Source abstract
Abstract
Mild-temperature photothermal therapy (mild PTT) is a safe and efficient antitumor therapy. However, mild PTT alone usually fails to activate the immune response and prevent tumor metastasis. Herein, a photothermal agent, copper sulfide@ovalbumin (CuS@OVA), with an effective PTT effect in the second near-infrared (NIR-II) window, is developed. CuS@OVA can optimize the tumor microenvironment (TME) and evoke an adaptive immune response. Copper ions are released in the acidic TME to promote the M1 polarization of tumor-associated macrophages. The model antigen OVA not only acts as a scaffold for nanoparticle growth but also promotes the maturation of dendritic cells, which primes naive T cells to stimulate adaptive immunity. CuS@OVA augments the antitumor efficiency of the immune checkpoint blockade (ICB) in vivo, which suppresses tumor growth and metastasis in a mouse melanoma model. The proposed therapeutic platform, CuS@OVA nanoparticles, may be a potential adjuvant for optimizing the TME and improving the efficiency of ICB as well as other antitumor immunotherapies. STATEMENT OF SIGNIFICANCE: Mild-temperature photothermal therapy (mild PTT) is a safe and efficient antitumor therapy, but usually fails to activate the immune response and prevent tumor metastasis. Herein, we develop a photothermal agent, copper sulfide@ovalbumin (CuS@OVA), with an excellent PTT effect in the second near-infrared (NIR-II) window. CuS@OVA can optimize the tumor microenvironment (TME) and evoke an adaptive immune response by promoting the M1 polarization of tumor-associated macrophages and the maturation of dendritic cells. CuS@OVA augments the antitumor efficiency of the immune checkpoint blockade (ICB) in vivo, suppressing tumor growth and metastasis. The platform may be a potential adjuvant for optimizing the TME and improving the efficiency of ICB as well as other antitumor immunotherapies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer, Stress, Anesthesia, and Immune Response
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Clinical development and potential of photothermal and photodynamic therapies for cancer10.1038/s41571-020-0410-2 ↗
2. Recent advances in nanoparticle-based photothermal therapy for breast cancer10.1016/j.jconrel.2022.06.050 ↗
3. NIR-II responsive molybdenum dioxide nanosystem manipulating cellular immunogenicity for enhanced tumor photoimmunotherapy10.1021/acs.nanolett.2c00899 ↗
4. Recent advancements on photothermal conversion and antibacterial applications over MXenes-based materials
5. A platelet-mimicking single-atom nanozyme for mitochondrial damage-mediated mild-temperature photothermal therapy10.1021/acsami.1c22346 ↗
6. Biomimetic nanoparticles for effective mild temperature photothermal therapy and multimodal imaging10.1016/j.jconrel.2022.05.010 ↗
7. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency
8. Plasmon-driven catalytic chemotherapy augments cancer immunotherapy through induction of immunogenic cell death and blockage of IDO pathway10.1002/adma.202102188 ↗
9. Recent advances in hyperthermia therapy-based synergistic immunotherapy10.1002/adma.202004788 ↗
10. Nanotechnology for multimodal synergistic cancer therapy10.1021/acs.chemrev.7b00258 ↗
11. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy10.1038/s41467-019-13204-3 ↗
12. Low-temperature photothermal therapy: strategies and applications10.34133/2021/9816594 ↗
13. The role of dendritic cells in cancer and anti-tumor immunity10.1016/j.smim.2021.101481 ↗
14. Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming10.1002/embj.201488027 ↗
15. Immunoengineering: how nanotechnology can enhance cancer immunotherapy10.1016/j.cell.2015.03.037 ↗
16. Personalized vaccines for cancer immunotherapy10.1126/science.aar7112 ↗
17. Nanobiomaterial-based vaccination immunotherapy of cancer10.1016/j.biomaterials.2021.120709 ↗
18. Efficient nanovaccine delivery in cancer immunotherapy10.1021/acsnano.7b00978 ↗
19. Efficient lymph node-targeted delivery of personalized cancer vaccines with reactive oxygen species-inducing reduced graphene oxide nanosheets10.1021/acsnano.0c05062 ↗
20. Cyclodextrin metal-organic frameworks and derivatives: recent developments and applications10.1039/D1CS00550B ↗
21. From synthesis to drug delivery and theranostics applications10.1016/j.addr.2022.114496 ↗
22. Key progresses of MOE key laboratory of macromolecular synthesis and functionalization in 2021
23. An aluminum adjuvant-integrated nano-MOF as antigen delivery system to induce strong humoral and cellular immune responses10.1016/j.jconrel.2019.02.035 ↗
24. Nanovaccine-based strategies to overcome challenges in the whole vaccination cascade for tumor immunotherapy10.1002/smll.202006000 ↗
25. Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors
26. Antigen-directed fabrication of a multifunctional nanovaccine with ultrahigh antigen loading efficiency for tumor photothermal-immunotherapy10.1002/adma.201704408 ↗
27. Tumour-associated macrophages as treatment targets in oncology10.1038/nrclinonc.2016.217 ↗
28. Endothelial extracellular vesicles promote tumour growth by tumour-associated macrophage reprogramming10.1002/jev2.12228 ↗
29. Macrophages in uveal melanoma and in experimental ocular tumor models: friends or foes?10.1016/j.preteyeres.2010.11.004 ↗
30. Tumor-associated macrophages in tumor immunity10.3389/fimmu.2020.583084 ↗
31. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets10.1186/s13045-022-01282-8 ↗
32. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma10.1016/j.jhep.2020.11.037 ↗
33. Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma10.1158/2326-6066.CIR-18-0448 ↗
34. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues10.1038/nnano.2016.168 ↗
35. Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma10.1016/j.biomaterials.2019.119464 ↗
36. Artificial natural killer cells for specific tumor inhibition and renegade macrophage re-education10.1002/adma.201904495 ↗
37. Reprogramming tumor-associated macrophages by nanoparticle-based reactive oxygen species photogeneration10.1021/acs.nanolett.8b03568 ↗
38. Copper-based nanoscale coordination polymers augmented tumor radioimmunotherapy for immunogenic cell death induction and T-Cell infiltration
39. Macrophage polarization10.1146/annurev-physiol-022516-034339 ↗
40. Recent advances in engineered materials for immunotherapy-involved combination cancer therapy10.1002/adma.202007630 ↗
41. Bortezomib-encapsulated CuS/carbon dot nanocomposites for enhanced photothermal therapy via stabilization of polyubiquitinated substrates in the proteasomal degradation pathway10.1021/acsnano.0c05332 ↗
42. Preclinical safety and hepatotoxicity evaluation of biomineralized copper sulfide nanoagents10.1186/s12951-022-01399-5 ↗
43. Adding the cancer genome atlas chromosome classes to american joint committee on cancer system offers more precise prognostication in uveal melanoma10.1016/j.ophtha.2021.11.018 ↗
44. Uveal melanoma: trends in incidence, treatment, and survival10.1016/j.ophtha.2011.01.040 ↗
45. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study10.1093/annonc/mdz176 ↗
46. First drug approved for rare eye cancer10.1158/2159-8290.CD-NB2022-0009 ↗
47. Photothermal-triggered immunogenic nanotherapeutics for optimizing osteosarcoma therapy by synergizing innate and adaptive immunity10.1016/j.biomaterials.2022.121383 ↗
48. Engineering, copper sulfide nanoparticle/cellulose composite paper: room-temperature green fabrication for NIR laser-inducible ablation of pathogenic microorganisms10.1021/acssuschemeng.6b03003 ↗
49. On-demand drug release nanoplatform based on fluorinated aza-BODIPY for imaging-guided chemo-phototherapy10.1016/j.biomaterials.2020.120211 ↗
50. An NIR discrete metallacycle constructed from perylene bisimide and tetraphenylethylene fluorophores for imaging-guided cancer radio-chemotherapy10.1002/adma.202106388 ↗
51. Smad3 promotes cancer-associated fibroblasts generation via macrophage-myofibroblast transition
52. High salt diet accelerates the progression of murine lupus through dendritic cells via the p38 MAPK and STAT1 signaling pathways10.1038/s41392-020-0139-5 ↗
53. Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma10.1158/1078-0432.CCR-18-1368 ↗
54. ZnS@BSA nanoclusters potentiate efficacy of cancer immunotherapy
55. Near-infrared-II light induced mild hyperthermia activate cisplatin-artemisinin nanoparticle for enhanced chemo/chemodynamic therapy and immunotherapy10.1002/smtd.202200379 ↗
56. Second near-infrared photothermal semiconducting polymer nanoadjuvant for enhanced cancer immunotherapy
57. Near-infrared-II activated inorganic photothermal nanomedicines10.1016/j.biomaterials.2020.120459 ↗
58. A zwitterionic polypeptide nanocomposite with unique NIR-I/II photoacoustic imaging for NIR-I/II cancer photothermal therapy10.1039/D1TB00823D ↗
59. Tumor-associated macrophages: from basic research to clinical application10.1186/s13045-017-0430-2 ↗
60. Copper sulfide nanoparticle-redirected macrophages for adoptive transfer therapy of melanoma
61. Copper induces cell death by targeting lipoylated TCA cycle proteins10.1126/science.abf0529 ↗
62. Reprogramming the tumor microenvironment through second-near-infrared-window photothermal genome editing of PD-L1 mediated by supramolecular gold nanorods for enhanced cancer immunotherapy
63. Fluorous-tagged peptide nanoparticles ameliorate acute lung injury via lysosomal stabilization and inflammation inhibition in pulmonary macrophages
64. Nanodiamonds act as Trojan horse for intracellular delivery of metal ions to trigger cytotoxicity10.1186/s12989-014-0075-z ↗
65. Light-driven sodium-pumping rhodopsin: a new concept of active transport10.1021/acs.chemrev.7b00548 ↗
66. Protein nanoparticle charge and hydrophobicity govern protein corona and macrophage uptake10.1021/acsami.0c12341 ↗
67. Light-triggered OVA release based on CuS@poly(lactide-co-glycolide acid) nanoparticles for synergistic photothermal-immunotherapy of tumor10.1016/j.phrs.2020.104902 ↗
68. Ssu72 regulates alveolar macrophage development and allergic airway inflammation by fine-tuning of GM-CSF receptor signaling10.1016/j.jaci.2020.07.038 ↗
69. Myeloid cell-targeted therapies for solid tumours10.1038/s41577-022-00737-w ↗
70. Regulation of type I interferon responses by mitochondria-derived reactive oxygen species in plasmacytoid dendritic cells10.1016/j.redox.2017.07.016 ↗
71. Human plasmacytoid and monocyte-derived dendritic cells display distinct metabolic profile upon RIG-I activation10.3389/fimmu.2018.03070 ↗
72. Redox regulation of the immune response10.1038/s41423-022-00902-0 ↗
73. Neoadjuvant checkpoint blockade for cancer immunotherapy10.1126/science.aax0182 ↗
74. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials10.1038/d41573-020-00204-y ↗
75. Primary, adaptive, and acquired resistance to cancer immunotherapy10.1016/j.cell.2017.01.017 ↗
76. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma10.1038/s41467-021-25332-w ↗
77. Trends in clinical development for PD-1/PD-L1 inhibitors10.1038/d41573-019-00182-w ↗
78. Defining and understanding adaptive resistance in cancer immunotherapy10.1016/j.it.2018.05.001 ↗
79. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-1210.1016/j.immuni.2018.09.024 ↗
80. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion10.1038/s41568-021-00339-z ↗
81. Mechanisms of tolerance induction by dendritic cells in vivo10.3389/fimmu.2018.00350 ↗
82. Myeloid-derived suppressor cells coming of age10.1038/s41590-017-0022-x ↗
83. TREM2 Modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy10.1016/j.cell.2020.07.013 ↗
84. Dual-channel theranostic system for quantitative self-indication and low-temperature synergistic therapy of cancer
85. Versatile types of inorganic/organic NIR-IIa/IIb fluorophores: from strategic design toward molecular imaging and theranostics10.1021/acs.chemrev.1c00553 ↗
86. Phagocytosis checkpoints as new targets for cancer immunotherapy10.1038/s41568-019-0183-z ↗
87. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: a TAM-pting approach10.1016/j.pharmthera.2021.107986 ↗
88. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity10.1038/nature22396 ↗
89. EMT, MET, plasticity, and tumor metastasis10.1016/j.tcb.2020.07.003 ↗
90. Surgical stress and cancer progression: the twisted tango10.1186/s12943-019-1058-3 ↗
91. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis10.1186/s13045-022-01347-8 ↗
92. Landscape of infiltrated immune cell characterization in uveal melanoma to improve immune checkpoint blockade therapy
93. Comprehensive analysis of cutaneous and uveal melanoma liver metastases10.1136/jitc-2020-001501 ↗
94. A novel stimuli-responsive injectable antibacterial hydrogel to achieve synergetic photothermal/gene-targeted therapy towards uveal melanoma
95. Nuclear-targeted photothermal therapy prevents cancer recurrence with near-infrared triggered copper sulfide nanoparticles10.1021/acsnano.7b06870 ↗
96. Starch capped atomically thin CuS nanocrystals for efficient photothermal therapy
97. Thermal ablation of tumours: biological mechanisms and advances in therapy10.1038/nrc3672 ↗
98. Emerging combination strategies with phototherapy in cancer nanomedicine10.1039/D0CS00215A ↗
99. Low temperature photothermal therapy: advances and perspectives10.1016/j.ccr.2021.214330 ↗
100. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review10.1016/j.ctrv.2017.08.009 ↗